The development of next-generation sequencing has enabled the identification of a wider range of pathogenic germline mutations that increase the carriers’ risk of being diagnosed with pancreatic cancer, including ATM, BRCA1, BRCA2, MLH1, MSH2, MSH6, TP53, PALB2, PMS2, PRSS1, STK11, and CDKN2A [12,22]. The gene discussed is TP53; the disease is pancreatic neoplasm.